论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
转移性胰腺导管腺癌患者中 FOLFIRINOX+toripalimab 的长期生存率:一病例报告
Authors Jiang T , Gao C, Luo Y , Ye Z, Wang B
Received 7 April 2022
Accepted for publication 3 August 2022
Published 25 August 2022 Volume 2022:15 Pages 883—890
DOI https://doi.org/10.2147/OTT.S369772
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr William C. Cho
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most fatal diseases, with its morbidity and mortality showing an upward trend. The application of monotonous immune checkpoint inhibitor (ICI) in PDAC comes to a disappointing endpoint, despite of its great advancements achieved in cancer treatment. However, a promising efficacy can be obtained on condition that ICIs are used in combination with chemotherapy.
Case: We reported a patient suffering from metastatic PDAC with proficient mismatch repair (pMMR) and low expression of programmed cell death ligand 1 (PD-L1). The patient survived for a remarkably long time and showed favorable tolerance to the combination of FOLFIRINOX+Toripalimab (a novel PD-1 inhibitor) administrated after chemoradiotherapy and targeted therapy. Today, the survival benefits gained from this therapy will continue to have a positive impact on him.
Conclusion: FOLFIRINOX+Toripalimab potentially serves as a novel therapeutic strategy for PDAC in late stage, with durable benefits and manageable toxicity in patients, which is still required to be validated in further research.
Keywords: pancreatic ductal adenocarcinoma, programmed cell death protein 1, chemotherapy, long-term survival, favorable tolerance